Viking Therapeutics (VKTX) Change in Accured Expenses (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Change in Accured Expenses data on file, last reported at $15.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 376.41% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $27.8 million (up 275.25% YoY), and the FY2025 full-year result was $6.2 million, up 6.05% from the prior year.
• Change in Accured Expenses rose to $15.9 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.9 million in Q1 2024 to a low of -$13.6 million in Q2 2024.
• A 5-year average of $1.9 million and a median of $694000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses tumbled 862.72% in 2023 and jumped 6472.88% in 2024, its largest moves.
• Tracing VKTX's Change in Accured Expenses over 5 years: stood at $2.5 million in 2022, then soared by 57.26% to $3.9 million in 2023, then sank by 299.8% to -$7.8 million in 2024, then jumped by 126.37% to $2.1 million in 2025, then surged by 667.81% to $15.9 million in 2026.
• Business Quant data shows VKTX's Change in Accured Expenses at $15.9 million in Q1 2026, $2.1 million in Q4 2025, and -$4.8 million in Q3 2025.